Baxter International Inc.
NYSE:BAXMedical - Instruments & Supplies
Healthcare
$26.16 -5.23%
-$1.07 today
- Market cap
- $13.53B
- Beta
- 0.64
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.13
- Dividend yield
- 1.03%
52W Low $15.73High $31.76
Volume 4.01M
Average 7.62M
Income Statement
Follow revenue through to earnings.
Revenue
$11.24B
FY 2025 · Annual
+5.7% YoYOperating Income
-$308.00M
FY 2025 · Annual
Net Income
-$957.00M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.15B | 10.06B | 10.36B | 10.64B | 11.24B |
| Cost of Revenue | 7.43B | 6.51B | 6.21B | 6.65B | 7.87B |
| Gross Profit | 4.72B | 3.55B | 4.15B | 3.98B | 3.38B |
| Gross Margin | 38.9% | 35.3% | 40.1% | 37.5% | 30.1% |
| Research & Development | 531M | 450M | 518M | 590M | 518M |
| Selling, General & Admin | 2.85B | 3.1B | 2.95B | 2.97B | 2.89B |
| Operating Expenses | 3.37B | 6.39B | 3.44B | 3.97B | 3.69B |
| Depreciation & Amortization | 867M | 1.07B | 984M | 997M | 981M |
| EBITDA | 2.19B | (1.76B) | 1.73B | 1.12B | 766M |
| EBITDA Margin | 18.0% | -17.5% | 16.7% | 10.5% | 6.8% |
| Operating Income | 1.35B | (2.85B) | 707M | 14M | (308M) |
| Operating Margin | 11.1% | -28.3% | 6.8% | 0.1% | -2.7% |
| Interest Income | 14M | 19M | 69M | 67M | 52M |
| Interest Expense | 207M | 413M | 508M | 408M | 290M |
| Other Income / Expenses | (234M) | (403M) | (465M) | (303M) | (197M) |
| Income Before Tax | 1.12B | (3.25B) | 242M | (289M) | (505M) |
| Pre-Tax Margin | 9.2% | -32.3% | 2.3% | -2.7% | -4.5% |
| Income Tax Expense | 83M | (135M) | 61M | 37M | 395M |
| Net Income | 1.28B | (2.43B) | 2.66B | (649M) | (957M) |
| Net Margin | 10.6% | -24.2% | 25.6% | -6.1% | -8.5% |
| EPS (Basic) | 2.56 | (4.83) | 5.25 | (1.27) | (1.75) |
| EPS (Diluted) | 2.53 | (4.83) | 5.23 | (1.27) | (1.75) |
| 502M | 504M | 506M | 510M | 513M | |
| 508M | 504M | 506M | 510M | 513M |
BAX Earnings Waterfall · TTM
NYSE:BAX · Revenue to Net Income
Key Ratios
EPS$-2.04
Gross Margin30.2%
Net Margin-9.0%
P/E Ratio-45.9
P/S Ratio3.6
Analysis
$11.5B of revenue converted into -$1.1B of net income for the selected period. Gross margin is 30.2% and net margin is -9.0%, showing how much revenue survives after costs and taxes. EPS is $-2.04, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 29, 2026 | |
| 10-Q | Quarterly report | Oct 29, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 2, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 18, 2026 |
How much revenue does BAX generate?
Baxter International Inc. (BAX) reported $11.24B of revenue in fiscal 2025.
Is BAX profitable?
Baxter International Inc. (BAX) reported -$957.00M of net income, with a net margin of -8.5%.
Continue the stock analysis
Jump to another research area for this company.